Manidipine Zydus (Manidipine Dihydrochloride)

• Manidipine is a dihydropyridine calcium‑channel blocker used in the management of high‑blood‑pressure disorders.
• Hypertension (essential): reduces systolic and diastolic blood pressure in adults with essential hypertension.
• Isolated systolic hypertension: helps lower elevated systolic pressure in older patients.
• Diastolic hypertension: assists in decreasing elevated diastolic pressure.

• Manidipine selectively blocks L‑type calcium channels in vascular smooth‑muscle cells, preventing calcium influx that is required for contraction. This inhibition causes dose‑dependent vasodilation of peripheral arterioles, decreasing systemic vascular resistance and thereby lowering arterial blood pressure. The drug’s affinity for vascular tissue exceeds that for cardiac tissue, providing antihypertensive effect with minimal negative inotropic activity.

Manidipine may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects

• Headache: mild to moderate headache reported.
• Flushing: transient facial warmth.
• Peripheral edema: swelling of ankles or feet.
• Dizziness: sensation of light‑headedness.
• Tachycardia: increased heart rate.
• Nausea: mild gastrointestinal discomfort.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure causing fainting.
• Angioedema: swelling of lips, tongue or airway.
• Hepatic dysfunction: elevated liver enzymes.
• Myocardial infarction: rare occurrence of heart attack.
• Arrhythmia: abnormal heart rhythm.
• Allergic reaction: rash, itching, or anaphylaxis.

• Before initiating therapy with Manidipine, several precautionary measures should be considered.
• Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension.
• Gradual dose titration: start with low dose and increase gradually as tolerated.
• Hepatic impairment: use with caution in patients with liver disease.
• Renal impairment: adjust therapy if severe renal dysfunction is present.
• Concomitant antihypertensives: monitor for additive blood‑pressure lowering effects.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Manidipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma levels and increase risk of hypotension.
• Grapefruit juice: can inhibit metabolism leading to higher drug exposure.
• Concurrent use with other potent antihypertensives: may cause excessive blood‑pressure reduction.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug concentrations and reduce effect.
• NSAIDs: may blunt antihypertensive response.